{"title":"Decorin the antifibrotic proteoglycan and its progression in therapy.","authors":"Kornélia Baghy, Helga Szakadáti, Ilona Kovalszky","doi":"10.1152/ajpcell.01075.2024","DOIUrl":null,"url":null,"abstract":"<p><p>Fibrosis, which underlies numerous chronic diseases, is characterized by excessive extracellular matrix (ECM) accumulation, resulting in disrupted tissue architecture. Decorin, a small leucine-rich proteoglycan synthesized primarily by fibroblasts and myoblasts, has emerged as a potent antifibrotic agent mainly by inhibiting transforming growth factor-β (TGF-β), which is a major driver of fibrosis in various tissues and organs such as the heart, eyes, skin, liver, muscle, etc. Numerous therapeutic applications of decorin showcase its ability to reduce fibrosis and improve tissue function. Advances in treatments utilizing recombinant protein, gene-delivery systems, and biomaterials, such as decorin-loaded hydrogels, have demonstrated decorin's potential to improve localized and systemic fibrosis therapies. This review discusses recent advances in decorin's antifibrotic potential and its therapeutic applications.</p>","PeriodicalId":7585,"journal":{"name":"American journal of physiology. Cell physiology","volume":" ","pages":"C1853-C1865"},"PeriodicalIF":5.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of physiology. Cell physiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1152/ajpcell.01075.2024","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Fibrosis, which underlies numerous chronic diseases, is characterized by excessive extracellular matrix (ECM) accumulation, resulting in disrupted tissue architecture. Decorin, a small leucine-rich proteoglycan synthesized primarily by fibroblasts and myoblasts, has emerged as a potent antifibrotic agent mainly by inhibiting transforming growth factor-β (TGF-β), which is a major driver of fibrosis in various tissues and organs such as the heart, eyes, skin, liver, muscle, etc. Numerous therapeutic applications of decorin showcase its ability to reduce fibrosis and improve tissue function. Advances in treatments utilizing recombinant protein, gene-delivery systems, and biomaterials, such as decorin-loaded hydrogels, have demonstrated decorin's potential to improve localized and systemic fibrosis therapies. This review discusses recent advances in decorin's antifibrotic potential and its therapeutic applications.
期刊介绍：
The American Journal of Physiology-Cell Physiology is dedicated to innovative approaches to the study of cell and molecular physiology. Contributions that use cellular and molecular approaches to shed light on mechanisms of physiological control at higher levels of organization also appear regularly. Manuscripts dealing with the structure and function of cell membranes, contractile systems, cellular organelles, and membrane channels, transporters, and pumps are encouraged. Studies dealing with integrated regulation of cellular function, including mechanisms of signal transduction, development, gene expression, cell-to-cell interactions, and the cell physiology of pathophysiological states, are also eagerly sought. Interdisciplinary studies that apply the approaches of biochemistry, biophysics, molecular biology, morphology, and immunology to the determination of new principles in cell physiology are especially welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
